Literature DB >> 32029389

The relationships between cancer and autoimmune rheumatic diseases.

Laura C Cappelli1, Ami A Shah2.   

Abstract

Links between autoimmune rheumatic diseases and cancer continue to be elucidated. In this review, we explore this complex, bidirectional relationship. First, the increased risk of cancer across the breadth of the autoimmune rheumatic diseases is described. The magnitude of risk and types of tumors seen can differ by the type of autoimmune disease, timing of disease course, and even clinical and laboratory features within a particular autoimmune disease, suggesting that targeted cancer screening strategies can be considered. Multiple mechanisms linking autoimmune rheumatic diseases and cancer are discussed, including the development of autoimmunity in the context of naturally occurring anti-tumor immune responses and malignancy arising in the context of inflammation and damage from autoimmunity. Immunosuppression for rheumatic disease can increase risk for certain types of cancers. Finally, immune checkpoint inhibitors, a type of cancer immunotherapy, which cause a variety of inflammatory syndromes of importance to rheumatologists, are reviewed.
Copyright © 2019 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoantibodies; Autoimmunity; Cancer; Immune checkpoint inhibitor

Mesh:

Year:  2020        PMID: 32029389      PMCID: PMC7295675          DOI: 10.1016/j.berh.2019.101472

Source DB:  PubMed          Journal:  Best Pract Res Clin Rheumatol        ISSN: 1521-6942            Impact factor:   4.098


  121 in total

1.  Antinuclear Matrix Protein 2 Autoantibodies and Edema, Muscle Disease, and Malignancy Risk in Dermatomyositis Patients.

Authors:  Jemima Albayda; Iago Pinal-Fernandez; Wilson Huang; Cassie Parks; Julie Paik; Livia Casciola-Rosen; Sonye K Danoff; Cheilonda Johnson; Lisa Christopher-Stine; Andrew L Mammen
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-11       Impact factor: 4.794

Review 2.  IL-2: the first effective immunotherapy for human cancer.

Authors:  Steven A Rosenberg
Journal:  J Immunol       Date:  2014-06-15       Impact factor: 5.422

3.  Arthritis After Cancer Immunotherapy: Symptom Duration and Treatment Response.

Authors:  Melanie H Smith; Anne R Bass
Journal:  Arthritis Care Res (Hoboken)       Date:  2018-08-23       Impact factor: 4.794

Review 4.  Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.

Authors:  Michael A Postow; Robert Sidlow; Matthew D Hellmann
Journal:  N Engl J Med       Date:  2018-01-11       Impact factor: 91.245

5.  Association of the autoimmune disease scleroderma with an immunologic response to cancer.

Authors:  Christine G Joseph; Erika Darrah; Ami A Shah; Andrew D Skora; Livia A Casciola-Rosen; Fredrick M Wigley; Francesco Boin; Andrea Fava; Chris Thoburn; Isaac Kinde; Yuchen Jiao; Nickolas Papadopoulos; Kenneth W Kinzler; Bert Vogelstein; Antony Rosen
Journal:  Science       Date:  2013-12-05       Impact factor: 47.728

6.  Immune-Related Adverse Events as a Biomarker in Non-Melanoma Patients Treated with Programmed Cell Death 1 Inhibitors.

Authors:  Julia Judd; Matthew Zibelman; Elizabeth Handorf; John O'Neill; Chethan Ramamurthy; Sasini Bentota; Jamie Doyle; Robert G Uzzo; Jessica Bauman; Hossein Borghaei; Elizabeth R Plimack; Ranee Mehra; Daniel M Geynisman
Journal:  Oncologist       Date:  2017-06-26

7.  Incidence and predictors of urotoxic adverse events in cyclophosphamide-treated patients with systemic necrotizing vasculitides.

Authors:  Guillaume Le Guenno; Alfred Mahr; Christian Pagnoux; Robin Dhote; Loïc Guillevin
Journal:  Arthritis Rheum       Date:  2011-05

8.  Increased incidence of cervical intraepithelial neoplasia in women with systemic lupus erythematosus treated with intravenous cyclophosphamide.

Authors:  Vladimir M Ognenovski; Wendy Marder; Emily C Somers; Carolyn M Johnston; Janice G Farrehi; Suzanne M Selvaggi; W Joseph McCune
Journal:  J Rheumatol       Date:  2004-09       Impact factor: 4.666

9.  Incidence of cancer among patients with systemic sclerosis in Korea: results from a single centre.

Authors:  K Y Kang; H W Yim; I-J Kim; J U Yoon; J H Ju; H-Y Kim; S-H Park
Journal:  Scand J Rheumatol       Date:  2009       Impact factor: 3.641

Review 10.  Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.

Authors:  L Khoja; D Day; T Wei-Wu Chen; L L Siu; A R Hansen
Journal:  Ann Oncol       Date:  2017-10-01       Impact factor: 32.976

View more
  10 in total

Review 1.  Cancer and Scleroderma.

Authors:  Emma Weeding; Livia Casciola-Rosen; Ami A Shah
Journal:  Rheum Dis Clin North Am       Date:  2020-06-10       Impact factor: 2.670

2.  Remission of anti-TIF1γ dermatomyositis after allogeneic hematopoietic stem cell transplant for myelodysplastic syndrome.

Authors:  Fatima Bawany; Bushra Tbakhi; Jason H Mendler; Christopher T Richardson; John M Bennett; Omar S Aljitawi
Journal:  Blood Adv       Date:  2020-11-24

Review 3.  Medications for Multiple Sclerosis and Risk of Malignancy: What Next?

Authors:  Daniel B Horton; Anthony T Reder
Journal:  Neurotherapeutics       Date:  2021-08-18       Impact factor: 6.088

Review 4.  Epstein-Barr Virus and Systemic Autoimmune Diseases.

Authors:  Gunnar Houen; Nicole Hartwig Trier
Journal:  Front Immunol       Date:  2021-01-07       Impact factor: 7.561

5.  Lung adenocarcinoma and sequential antineutrophil cytoplasmic antibody-associated vasculitis: a case report.

Authors:  Chun-Yang Zhang; Ran Miao; Wei Li; Hao-Yong Ning; Xiang-En Meng; Zhi-Hai Han; Feng Qin; Ying-Kui Liang; Ming-Xv Li
Journal:  J Int Med Res       Date:  2021-02       Impact factor: 1.671

Review 6.  PD-1/PD-L1 Inhibitors in Patients With Preexisting Autoimmune Diseases.

Authors:  Ke Zhang; Xiangyi Kong; Yuan Li; Zhongzhao Wang; Lin Zhang; Lixue Xuan
Journal:  Front Pharmacol       Date:  2022-03-18       Impact factor: 5.810

7.  Retrospective analysis of clinical trial safety data for pembrolizumab reveals the effect of co-occurring infections on immune-related adverse events.

Authors:  Tigran Makunts; Keith Burkhart; Ruben Abagyan; Peter Lee
Journal:  PLoS One       Date:  2022-02-10       Impact factor: 3.240

8.  Chronic Infection with Hidden Malignancy Mimicking the Clinical Presentation of an Autoimmune Disease.

Authors:  Ammar Bakhsh; Khalil Miyajan; Abdulghani Sadaqa; Amer Eisa; Ghali Faidah; Hani Almoallim
Journal:  Case Rep Rheumatol       Date:  2022-07-18

9.  Risk of Cancer in Connective Tissue Diseases in Northeastern Italy over 15 Years.

Authors:  Elena Treppo; Federica Toffolutti; Valeria Manfrè; Martina Taborelli; Ginevra De Marchi; Salvatore De Vita; Diego Serraino; Luca Quartuccio
Journal:  J Clin Med       Date:  2022-07-22       Impact factor: 4.964

Review 10.  New lung mass in a patient with granulomatosis with polyangiitis.

Authors:  Anna Masiak; Jadwiga Fijałkowska; Szymon Nowakowski; Żaneta Smoleńska; Zbigniew Zdrojewski
Journal:  Rheumatol Int       Date:  2020-07-16       Impact factor: 2.631

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.